Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023
Abstract Background The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level. This study aimed to assess biosimilar uptake in the case of trastuzumab and to explore potential factors influencing the bio...
Saved in:
Main Authors: | Qiyou Wu (Author), Zhitao Wang (Author), Yihan Fu (Author), Ren Luo (Author), Jing Sun (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
by: Qiyou Wu, et al.
Published: (2023) -
Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018) -
Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021) -
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021) -
Biosimilar medicines uptake: The role of the clinical pharmacist
by: Roland Nnaemeka Okoro
Published: (2021)